Most sickle cell disease patients who received the gene-editing therapy Casgevy have been free from vaso-occlusive crises for ...
Invisible complications of sickle cell disease can result in a lack of understanding and proper care, says columnist.
The majority of SCD patients given Lyfgenia in clinical trials remained free of vaso-occlusive events (VOEs) following ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback